Galanin immunoreactivity is increased in the nucleus basalis of Meynert in Alzheimer's disease
- PMID: 1699471
- DOI: 10.1002/ana.410280207
Galanin immunoreactivity is increased in the nucleus basalis of Meynert in Alzheimer's disease
Abstract
A depletion of large cholinergic neurons in the nucleus basalis of Meynert is a consistent finding in Alzheimer's disease (AD). The nucleus basalis of Meynert also contains interneurons and afferents that may modulate its functioning. In the present study we examined neurochemical markers for neuropeptides, amino acid neurotransmitters, and monoaminergic neurotransmitters in postmortem samples of the nucleus basalis in 16 control subjects and 30 patients with AD. There were no significant changes in glutamate, aspartate, taurine, gamma-aminobutyric acid (GABA), and catecholamines; however, concentrations of serotonin, 5-hydroxyindoleacetic acid, and 5-hydroxytryptophol were significantly reduced. Choline acetyltransferase activity was significantly reduced, consistent with previous reports. Galanin immunoreactivity was significantly increased twofold in the patients with AD, but there were no significant changes in substance P, somatostatin, or neuropeptide Y immunoreactivity. Since galanin inhibits acetylcholine release, and produces cognitive deficits in animals, increased galanin immunoreactivity in the nucleus basalis of Meynert in AD may contribute to the cognitive deficits that characterize the illness.
Similar articles
-
Monoaminergic and cholinergic synaptic markers in the nucleus basalis of Meynert (nbM): normal age-related changes and the effect of heart disease and Alzheimer's disease.Ann Neurol. 1992 Jun;31(6):611-20. doi: 10.1002/ana.410310608. Ann Neurol. 1992. PMID: 1355334
-
Galanin hyperinnervates surviving neurons of the human basal nucleus of Meynert in dementias of Alzheimer's and Parkinson's disease: a hypothesis for the role of galanin in accentuating cholinergic dysfunction in dementia.J Comp Neurol. 1988 Jul 22;273(4):543-57. doi: 10.1002/cne.902730409. J Comp Neurol. 1988. PMID: 2463283
-
Preservation of nucleus basalis neurons containing choline acetyltransferase and the vesicular acetylcholine transporter in the elderly with mild cognitive impairment and early Alzheimer's disease.J Comp Neurol. 1999 Sep 6;411(4):693-704. J Comp Neurol. 1999. PMID: 10421878 Clinical Trial.
-
The neurochemistry of Alzheimer's disease.Acta Neurol Belg. 1997 Jun;97(2):67-84. Acta Neurol Belg. 1997. PMID: 9246374 Review.
-
[Neuromodulators and Alzheimer's disease].Encephale. 1988 Sep-Oct;14(5):345-51. Encephale. 1988. PMID: 2463900 Review. French.
Cited by
-
Galanin fiber hyperinnervation preserves neuroprotective gene expression in cholinergic basal forebrain neurons in Alzheimer's disease.J Alzheimers Dis. 2009;18(4):885-96. doi: 10.3233/JAD-2009-1196. J Alzheimers Dis. 2009. PMID: 19749437 Free PMC article.
-
Galanin transgenic mice display cognitive and neurochemical deficits characteristic of Alzheimer's disease.Proc Natl Acad Sci U S A. 2001 Mar 27;98(7):4184-9. doi: 10.1073/pnas.061445598. Epub 2001 Mar 20. Proc Natl Acad Sci U S A. 2001. PMID: 11259657 Free PMC article.
-
Maternal Choline Supplementation Alters Basal Forebrain Cholinergic Neuron Gene Expression in the Ts65Dn Mouse Model of Down Syndrome.Dev Neurobiol. 2019 Jul;79(7):664-683. doi: 10.1002/dneu.22700. Epub 2019 Jun 9. Dev Neurobiol. 2019. PMID: 31120189 Free PMC article.
-
Coadministration of galanin antagonist M40 with a muscarinic M1 agonist improves delayed nonmatching to position choice accuracy in rats with cholinergic lesions.J Neurosci. 1998 Jul 1;18(13):5078-85. doi: 10.1523/JNEUROSCI.18-13-05078.1998. J Neurosci. 1998. PMID: 9634573 Free PMC article.
-
Fronto-temporal galanin modulates impulse control.Psychopharmacology (Berl). 2020 Feb;237(2):291-303. doi: 10.1007/s00213-019-05365-2. Epub 2019 Nov 8. Psychopharmacology (Berl). 2020. PMID: 31705163 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical